Arcus Biosciences, Inc. (RCUS)
NYSE: RCUS · Real-Time Price · USD
19.31
-0.25 (-1.28%)
Nov 7, 2025, 4:00 PM EST - Market closed
Arcus Biosciences Stock Forecast
Stock Price Forecast
The 8 analysts that cover Arcus Biosciences stock have a consensus rating of "Buy" and an average price target of $27.63, which forecasts a 43.09% increase in the stock price over the next year. The lowest target is $14 and the highest is $56.
Price Target: $27.63 (+43.09%)
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for Arcus Biosciences stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | May '25 | Jun '25 | Jul '25 | Aug '25 | Sep '25 | Oct '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 3 | 1 | 1 | 3 |
| Buy | 6 | 6 | 6 | 5 | 5 | 3 |
| Hold | 2 | 2 | 2 | 2 | 2 | 2 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 11 | 11 | 11 | 8 | 8 | 8 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Goldman Sachs | Goldman Sachs | Hold Maintains $14 → $16 | Hold | Maintains | $14 → $16 | -17.14% | Oct 30, 2025 |
| Citigroup | Citigroup | Strong Buy Maintains $54 → $56 | Strong Buy | Maintains | $54 → $56 | +190.01% | Oct 29, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $24 → $28 | Strong Buy | Maintains | $24 → $28 | +45.00% | Oct 29, 2025 |
| Wells Fargo | Wells Fargo | Buy Maintains $25 → $29 | Buy | Maintains | $25 → $29 | +50.18% | Oct 20, 2025 |
| Citigroup | Citigroup | Strong Buy Maintains $47 → $54 | Strong Buy | Maintains | $47 → $54 | +179.65% | Oct 13, 2025 |
Financial Forecast
Revenue This Year
241.82M
from 258.00M
Decreased by -6.27%
Revenue Next Year
147.61M
from 241.82M
Decreased by -38.96%
EPS This Year
-3.73
from -3.14
EPS Next Year
-4.26
from -3.73
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 266.7M | 310.7M | |||
| Avg | 241.8M | 147.6M | |||
| Low | 223.4M | 36.3M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 3.4% | 28.5% | |||
| Avg | -6.3% | -39.0% | |||
| Low | -13.4% | -85.0% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -3.65 | -3.07 | |||
| Avg | -3.73 | -4.26 | |||
| Low | -3.76 | -5.12 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | |||
| Avg | - | - | |||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.